Selvita SA
WSE:SLV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (13.8), the stock would be worth zł52.26 (49% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 9.2 | zł35 |
0%
|
| 3-Year Average | 13.8 | zł52.26 |
+49%
|
| 5-Year Average | 14.2 | zł53.87 |
+54%
|
| Industry Average | 12.3 | zł46.9 |
+34%
|
| Country Average | 7.6 | zł28.86 |
-18%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| PL |
S
|
Selvita SA
WSE:SLV
|
642.4m PLN | 9.2 | -222 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
962.6B USD | 1 651.2 | 3 990.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.9B USD | 21 | 25.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
127.8B USD | 19.9 | 34.7 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 36.6 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
299.9B CNY | 17.4 | 15.7 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | 29 | -122 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 23.4 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.4B USD | 45.1 | 45.8 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.8B USD | 10.5 | 20.5 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 27.2 | 29.9 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 4.2 |
| Median | 7.6 |
| 70th Percentile | 13.6 |
| Max | 13 949.2 |
Other Multiples
Selvita SA
Glance View
Selvita SA engages in the discovery, regulatory studies, as well as research and development. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 878 full-time employees. The company went IPO on 2019-10-16. The firm is engaged in providing multidisciplinary solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development. The company offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research, from target validation up to the selection of a clinical candidate. Also, it offers services at every stage of the drug discovery process in the field of drug testing and bioanalytical analyses, from development and validation of methods, stability studies, to routine quality control testing. The firm cooperates with numerous research institutes and universities from Europe and the United States.
